

## ■ General Information

### Applications

- Immunohistochemistry
  - TUNEL for apoptosis
- In situ hybridization (ISH)
  - mRNA
  - miRNA
  - Fluorescent In situ hybridization (FISH)

### Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

### How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Sectioned by microtome in 4 µm thickness

### Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times.
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

### Slide orientation

- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area	1	2	3	4	5	6	7	8	9	10
	11	12	13	14	15	16	17	18	19	20
	21	22	23	24	25	26	27	28	29	30
	30	32	33	34	35	36	37	38	39	40
	41	42	43	44	45	46	47	48	49	50
	51	52	53	54	55	56	57	58	59	60

## ■ Tissue types\*

The "tissue type" column in the data sheet denotes the following categories.

1. normal tissue from a non-cancer patient
2. normal tissue from a cancer patient, but the cancer involves unrelated organ
3. normal tissue adjacent to the cancer
4. benign tumor
5. tumor of borderline malignancy or uncertain malignant potential
6. cancer

## NBP2-30264 - Human Multi-tissue Tissue MicroArray (Cancer)

No.	Age	Sex	Organ	Diagnosis	pTNM	Stage		NBP2-30217#	Tissue type**
1	62	F	Endometrium	adenocarcinoma	T3cN0M0	III C	.	.	6
2	52	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	D**	.	6
3	57	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	D**	.	6
4	35	F	Endometrium	adenocarcinoma, endometrioid type	T1b1N0M0	I B1	.	.	6
5	38	F	Endometrium	adenocarcinoma	T1aN0M0	I A	.	105	6
6	53	F	Endometrium	adenocarcinoma, endometrioid type	T2bN0M0	II B	.	106	6
7	41	F	Endometrium	adenocarcinoma, endometrioid type	T3aN0M0	III A	.	107	6
8	49	F	Endometrium	adenocarcinoma, endometrioid type	T1aN0M0	I A	D**	.	6
9	53	F	Endometrium	adenocarcinoma, endometrioid type	T2N0M0	II	D**	109	6
10	52	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	.	110	6
11	68	F	Gallbladder	metastatic adenocarcinoma from stomach	.	IV	.	.	6
12	67	F	Gallbladder	adenocarcinoma, moderately differentiated	T4N0M0	III	.	112	6
13	52	F	Gallbladder	adenocarcinoma, poorly differentiated	T3N0M0	II A	.	113	6
14	54	F	Gallbladder	adenosquamous carcinoma	T3N0M1	IV	.	114	6
15	64	F	Gallbladder	adenocarcinoma, moderately differentiated	T3N1M0	II B	.	.	6
16	82	F	Gallbladder	adenocarcinoma, well differentiated	T4N0M1	IV	.	.	6
17	50	M	Gallbladder	adenocarcinoma, well differentiated	T2N1M0	II B	.	.	6
18	52	M	Gallbladder	adenocarcinoma, moderately differentiated	T3N0M0	II A	.	.	6
19	64	M	Gallbladder	adenocarcinoma, well differentiated	T2N0M0	I B	.	.	6
20	54	F	Gallbladder	adenocarcinoma, well differentiated	T2N0M0	I B	.	.	6
21	51	M	Larynx	squamous cell carcinoma, well differentiated	T4aN1M0	IVA	.	.	6
22	52	M	Larynx	squamous cell carcinoma, poorly differentiated	T4aN1M0	IVA	.	.	6
23	68	M	Larynx	adenoid cystic carcinoma, largely solid type	T4aN2bM0	IVA	.	123	6
24	71	M	Larynx	squamous cell carcinoma, moderately differentiated	T3N2bM0	IVA	.	.	6
25	50	M	Larynx	squamous cell carcinoma	T4aN0M0	IVA	.	125	6
26	61	F	Larynx	squamous cell carcinoma, moderately differentiated	T3N2bM0	IVA	.	126	6
27	69	M	Larynx	squamous cell carcinoma, well differentiated	T3N0M0	III	.	127	6
28	60	M	Epiglottis	squamous cell carcinoma, well differentiated	T4aN1M0	IVA	.	128	6
29	71	M	Oral cavity	squamous cell carcinoma, well differentiated	T4bNXM0	IVB	.	129	6
30	56	M	Larynx	squamous cell carcinoma, well differentiated	T3N0M0	III	.	130	6
31	64	F	Uterine cervix	squamous cell carcinoma	T1b1N0M0	I B1	I B*	.	6
32	59	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II A*	132	6
33	56	F	Uterine cervix	adenosquamous cell carcinoma	T2aN0M0	II A	II B*	133	6
34	50	F	Uterine cervix	squamous cell carcinoma	T1b1N1M0	III B	II A*	.	6
35	51	F	Uterine cervix	squamous cell carcinoma	T3bN1M0	III B	II A*	135	6
36	32	F	Uterine cervix	squamous cell carcinoma	T1bN1M0	III B	II B*	.	6
37	42	F	Uterine cervix	squamous cell carcinoma	T1bN1M0	III B	II A*	.	6
38	63	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II B*	.	6
39	42	F	Uterine cervix	squamous cell carcinoma	T1bN0M0	I B	II B*	.	6
40	71	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II B*	140	6
41	26	M	Neck	malignant lymphoma, B cell origin	.	■	.	.	6
42	53	M	Bone, femur	malignant lymphoma, probably B cell origin	.	IV	.	.	6
43	83	M	Jejunum	malignant lymphoma, B cell origin	.	IV	.	.	6
44	43	M	Cecum	malignant lymphoma, B cell origin	.	■ E	.	144	6
45	69	M	Stomach	malignant lymphoma, probably B cell origin	.	■ E	.	145	6
46	63	M	Retroperitoneum	malignant lymphoma, probably B cell origin	.	■	.	.	6
47	49	M	Stomach	malignant lymphoma, B cell origin	.	II E	.	.	6
48	51	M	Testis	malignant lymphoma, probably B cell origin	.	■ E	.	.	6
49	60	F	Stomach	malignant lymphoma, B cell origin	.	■ E	.	149	6
50	69	M	Duodenum	malignant lymphoma, probably B cell origin	.	■ E	.	.	6
51	66	M	Skin, sole	malignant melanoma	T4aNXXM	II B	.	.	6
52	44	F	Anus	malignant melanoma	.	.	.	152	6
53	20	M	Skin, toe	malignant melanoma	T3aN2bM0	III B	.	.	6
54	22	F	Skin, scalp	malignant melanoma	T4bNXM0	II C	.	154	6
55	53	M	Skin, hip	malignant melanoma	T4aN2bM0	III B	.	.	6
56	73	F	Skin, abdomen	malignant melanoma	T4aNXM1	IV	.	.	6
57	33	F	Skin, buttock	malignant melanoma	TXNXM1	IV	.	156	6
58	47	M	Skin, axilla	malignant melanoma	T4bNXM1	IV	.	.	6
59	74	F	Maxillary sinus	malignant melanoma	.	.	.	.	6
60	.	.	Carbon	.	.	.	.	.	.

#: The normal tissue in NBP2-30217 of corresponding number is from the identical patient.

\*, Clinical stage; \*\*D (#2, 3, 8, 9), double ovary and endometrial cancers.

TNM and Stage: AJCC Cancer Staging Manual (6th Edition)